Abstract: The present disclosure provides a method of preparing a pharmaceutical composition. The method includes transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel. The excipient mixture transferred from the second vessel includes a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient comprising a low-molecular weight poly(ethylene oxide) polymer. The method further includes contacting at least one pharmaceutically-active compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the polymer, and the compound. Before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of the at least one pharmaceutically-active compound.

Abstract: The present disclosure provides a method of preparing a pharmaceutical composition. The method includes transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel. The excipient mixture transferred from the second vessel includes a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient comprising a low-molecular weight poly(ethylene oxide) polymer. The method further includes contacting at least one pharmaceutically-active compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the polymer, and the compound. Before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of the at least one pharmaceutically-active compound.

Abstract: Compositions containing albuterol, ipratropium, and a propellant as well as aerosol canisters and inhalers, such as metered dose inhalers, containing such compositions.

Abstract: The present disclosure provides a method of preparing a pharmaceutical composition. The method includes transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel. The excipient mixture transferred from the second vessel includes a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient comprising a low-molecular weight poly(ethylene oxide) polymer. The method further includes contacting at least one pharmaceutically-active compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the polymer, and the compound. Before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of the at least one pharmaceutically-active compound.

Abstract: An electrical port is integrated within a side view mirror assembly of an automotive vehicle. The electrical port is electrically connected with a charging system of the vehicle. The electrical port may be coupled with a power source remote from the vehicle to power the charging system. The electrical port may be concealed or exposed depending on a position of the side view mirror assembly.

Abstract: A vehicle wireless information system includes a vehicle, an onboard vehicle computer provided in the vehicle and at least one external access point adapted to wirelessly access the onboard vehicle computer.

Abstract: The present invention is generally directed to a retractable overhead charging cord dispenser which has multi-positioning capability to provide plug-in electric power to PHEVs parked at various positions in a garage or the like. An illustrative embodiment of the retractable overhead charging cord dispenser includes an arm assembly, a cord guide arm carried by the arm assembly, a cord storage device provided in the arm assembly and a retractable charging cord extendable from the cord storage device and extending through and protruding from the cord guide arm.

Abstract: Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula —[X—R1—C(O)]— wherein each R1 is an independently selected organic group that links the —X— group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Abstract: An electrical port is integrated within a side view mirror assembly of an automotive vehicle. The electrical port is electrically connected with a charging system of the vehicle. The electrical port may be coupled with a power source remote from the vehicle to power the charging system. The electrical port may be concealed or exposed depending on a position of the side view mirror assembly.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: A pharmaceutical suspension aerosol formulation containing HFA-227 as a propellant.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula —[X—R1—C(O)]— wherein each R1 is an independently selected organic group that links the —X— group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Abstract: Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula —[X—R1—C(O)]— wherein each R1 is an independently selected organic group that links the —X— group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Abstract: Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.

Abstract: A computer controlled laser material processing system has a plurality of laser sources the beams of which are selectively operable between two modes. In a first raster engraving mode the beams are separated and independently controllable in synchronism with the motions of a beam delivery system to form plural, parallel, spaced apart scan lines on the surface of the workpiece for affecting the surface at high speed. In a second vector cutting mode the beams are combined such that they are collinear and have a power approximately equal to the sum of the powers of each individual laser source for cutting the surface at high power.

Abstract: A gas laser RF power supply has two RF oscillators operating at different frequencies, the first frequency to provide maximum RF voltage to the plasma tube prior to ignition, and the second frequency to provide optimum power for sustaining CW or pulse operation of the laser. The oscillator outputs are modulated to control power to the tube, the one in the form of RF pulses at the first frequency and at a power level below the laser emission threshold, and the other in CW or pulse form at the second frequency at a laser gas medium excitation level above the laser emission threshold. The first frequency is the resonance frequency of the tube prior to plasma ignition and the frequency of minimum average RF power required for a reliable ignition. The second frequency is the most efficient operating frequency for the plasma ignited and kept ionized by the pulses of the first frequency and provides maximum output laser power.